# TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

> **NCT04701476** · PHASE2 · RECRUITING · sponsor: **Teclison Ltd.** · enrollment: 110 (estimated)

## Conditions studied

- Colorectal Cancer; Lung Cancer

## Interventions

- **DRUG:** TATE and pembrolizumab
- **DRUG:** TAS-102 pill
- **DRUG:** Regorafenib Pill

## Key facts

- **NCT ID:** NCT04701476
- **Lead sponsor:** Teclison Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-20
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-09-30
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04701476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04701476, "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04701476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*